An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast–ovarian cancer syndrome

Lignende værker

• An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma
  af: Talreja, Vikas T., et al.
  Udgivet: (2019)
• Synchronous primary of periampullary and lung cancer: A case report and review of literature
  af: Vikas Talreja, et al.
  Udgivet: (2018-01-01)
• Lorlatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
  af: Talreja, Vikas T., et al.
  Udgivet: (2020)
• Use of lorlatinib subsequent to crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
  af: Talreja, Vikas T., et al.
  Udgivet: (2019)
• Metastatic Renal Cell Cancer—Systemic Therapy
  af: Joshi, Amit, et al.
  Udgivet: (2018)